Exact Mass: 995.980931
Exact Mass Matches: 995.980931
Found 72 metabolites which its exact mass value is equals to given mass value 995.980931
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Diadenosine hexaphosphate
Diadenosine hexaphosphate (AP6A) is a diadenosine polyphosphate. Diadenosine polyphosphates (APnAs, n = 3-6) are a family of endogenous vasoactive purine dinucleotides which have been isolated from thrombocytes. APnAs have been demonstrated to be involved in the control of vascular tone as well as the growth of vascular smooth muscle cells and hence, possibly, in atherogenesis. APnAs isolated substances are AP3A, AP4A, AP5A, and AP6A. APnAs are naturally occurring substances that facilitate tear secretion; they are released from the corneal epithelium, they stimulate tear production and therefore they may be considered as physiological modulators of tear secretion. The APnAs were discovered in the mid-sixties in the course of studies on aminoacyl-tRNA synthetases (aaRS). APnAs have emerged as intracellular and extracellular signalling molecules implicated in the maintenance and regulation of vital cellular functions and become considered as second messengers. Great variety of physiological and pathological effects in mammalian cells was found to be associated with alterations of APnAs. APnAs are polyphosphated nucleotidic substances which are found in the CNS and are known to be released in a calcium-dependent manner from storage vesicles in brain synaptosomes. AP6A is an avid inhibitor of eosinophil-derived neurotoxin (EDN). EDN is a catalytically proficient member of the pancreatic ribonuclease superfamily secreted along with other eosinophil granule proteins during innate host defense responses and various eosinophil-related inflammatory and allergic diseases. The ribonucleolytic activity of EDN is central to its antiviral and neurotoxic activities and possibly to other facets of its biological activity. AP6A have been demonstrated to be involved in the control of vascular tone as well as the growth of vascular smooth muscle cells and hence, possibly, in atherogenesis. AP6A have been identified in human platelets and shown to be an important modulator of cardiovascular function. (PMID: 11212966, 12738682, 11810214, 9607303, 8922753, 16401072, 12738682, 10094777). Diadenosine hexaphosphate (AP6A) is a diadenosine polyphosphate. Diadenosine polyphosphates (APnAs, n = 3-6) are a family of endogenous vasoactive purine dinucleotides which have been isolated from thrombocytes. APnAs have been demonstrated to be involved in the control of vascular tone as well as the growth of vascular smooth muscle cells and hence, possibly, in atherogenesis. APnAs isolated substances are AP3A, AP4A, AP5A, and AP6A. APnAs are naturally occurring substances that facilitate tear secretion; they are released from the corneal epithelium, they stimulate tear production and therefore they may be considered as physiological modulators of tear secretion. The APnAs were discovered in the mid-sixties in the course of studies on aminoacyl-tRNA synthetases (aaRS). APnAs have emerged as intracellular and extracellular signalling molecules implicated in the maintenance and regulation of vital cellular functions and become considered as second messengers. Great variety of physiological and pathological effects in mammalian cells was found to be associated with alterations of APnAs. APnAs are polyphosphated nucleotidic substances which are found in the CNS and are known to be released in a calcium-dependent manner from storage vesicles in brain synaptosomes. AP6A is an avid inhibitor of eosinophil-derived neurotoxin (EDN). EDN is a catalytically proficient member of the pancreatic ribonuclease superfamily secreted along with other eosinophil granule proteins during innate host defense responses and various eosinophil-related inflammatory and allergic diseases. The ribonucleolytic activity of EDN is central to its antiviral and neurotoxic activities and possibly to other facets of its biological activity. D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
(1,10-PHENANTHROLINE)TRIS[4,4,4-TRIFLUORO-1-(2-THIENYL)-1,3-BUTANEDIONATO]EUROPIUM(III),98.0(T)
C36H20EuF9N2O6S3 (995.9552178)
EuropiuM, (1,10-phenanthroline-kN1,kN10)tris[4,4,4-trifluoro-1-(2-thienyl)-1,3-butanedionato-kO1,kO3]-
C36H20EuF9N2O6S3 (995.9552178)
N-[(4E,8E,12E)-1,3-dihydroxytricosa-4,8,12-trien-2-yl]tetratetracontanamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxytritriaconta-4,8,12-trien-2-yl]tetratriacontanamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxyhentriaconta-4,8,12-trien-2-yl]hexatriacontanamide
C67H129NO3 (995.9971923999999)
(22Z,25Z,28Z)-N-(1,3-dihydroxyhentriacontan-2-yl)hexatriaconta-22,25,28-trienamide
C67H129NO3 (995.9971923999999)
(21Z,24Z)-N-[(E)-1,3-dihydroxypentatriacont-4-en-2-yl]dotriaconta-21,24-dienamide
C67H129NO3 (995.9971923999999)
(Z)-N-[(4E,8E)-1,3-dihydroxytricosa-4,8-dien-2-yl]tetratetracont-33-enamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxyhexatriaconta-4,8,12-trien-2-yl]hentriacontanamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxytetratriaconta-4,8,12-trien-2-yl]tritriacontanamide
C67H129NO3 (995.9971923999999)
(Z)-N-[(4E,8E)-1,3-dihydroxyheptacosa-4,8-dien-2-yl]tetracont-29-enamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxyoctacosa-4,8,12-trien-2-yl]nonatriacontanamide
C67H129NO3 (995.9971923999999)
(33Z,36Z)-N-[(E)-1,3-dihydroxytricos-4-en-2-yl]tetratetraconta-33,36-dienamide
C67H129NO3 (995.9971923999999)
(25Z,28Z)-N-[(E)-1,3-dihydroxyhentriacont-4-en-2-yl]hexatriaconta-25,28-dienamide
C67H129NO3 (995.9971923999999)
(18Z,21Z,24Z)-N-(1,3-dihydroxypentatriacontan-2-yl)dotriaconta-18,21,24-trienamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxydotriaconta-4,8,12-trien-2-yl]pentatriacontanamide
C67H129NO3 (995.9971923999999)
(Z)-N-[(4E,8E)-1,3-dihydroxytritriaconta-4,8-dien-2-yl]tetratriacont-23-enamide
C67H129NO3 (995.9971923999999)
(29Z,32Z)-N-[(E)-1,3-dihydroxyheptacos-4-en-2-yl]tetraconta-29,32-dienamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxytetracosa-4,8,12-trien-2-yl]tritetracontanamide
C67H129NO3 (995.9971923999999)
(30Z,33Z,36Z)-N-(1,3-dihydroxytricosan-2-yl)tetratetraconta-30,33,36-trienamide
C67H129NO3 (995.9971923999999)
(28Z,31Z,34Z)-N-(1,3-dihydroxypentacosan-2-yl)dotetraconta-28,31,34-trienamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxyheptatriaconta-4,8,12-trien-2-yl]triacontanamide
C67H129NO3 (995.9971923999999)
(26Z,29Z,32Z)-N-(1,3-dihydroxyheptacosan-2-yl)tetraconta-26,29,32-trienamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxyhexacosa-4,8,12-trien-2-yl]hentetracontanamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxytriaconta-4,8,12-trien-2-yl]heptatriacontanamide
C67H129NO3 (995.9971923999999)
(23Z,26Z)-N-[(E)-1,3-dihydroxytritriacont-4-en-2-yl]tetratriaconta-23,26-dienamide
C67H129NO3 (995.9971923999999)
(Z)-N-[(4E,8E)-1,3-dihydroxyheptatriaconta-4,8-dien-2-yl]triacont-19-enamide
C67H129NO3 (995.9971923999999)
(20Z,23Z,26Z)-N-(1,3-dihydroxytritriacontan-2-yl)tetratriaconta-20,23,26-trienamide
C67H129NO3 (995.9971923999999)
(Z)-N-[(4E,8E)-1,3-dihydroxypentacosa-4,8-dien-2-yl]dotetracont-31-enamide
C67H129NO3 (995.9971923999999)
(16Z,19Z,22Z)-N-(1,3-dihydroxyheptatriacontan-2-yl)triaconta-16,19,22-trienamide
C67H129NO3 (995.9971923999999)
(Z)-N-[(4E,8E)-1,3-dihydroxyhentriaconta-4,8-dien-2-yl]hexatriacont-25-enamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxyoctatriaconta-4,8,12-trien-2-yl]nonacosanamide
C67H129NO3 (995.9971923999999)
(Z)-N-[(4E,8E)-1,3-dihydroxynonacosa-4,8-dien-2-yl]octatriacont-27-enamide
C67H129NO3 (995.9971923999999)
(31Z,34Z)-N-[(E)-1,3-dihydroxypentacos-4-en-2-yl]dotetraconta-31,34-dienamide
C67H129NO3 (995.9971923999999)
(Z)-N-[(4E,8E)-1,3-dihydroxypentatriaconta-4,8-dien-2-yl]dotriacont-21-enamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxypentatriaconta-4,8,12-trien-2-yl]dotriacontanamide
C67H129NO3 (995.9971923999999)
(19Z,22Z)-N-[(E)-1,3-dihydroxyheptatriacont-4-en-2-yl]triaconta-19,22-dienamide
C67H129NO3 (995.9971923999999)
(21Z,24Z)-N-[(8E,12E)-1,3,4-trihydroxytriaconta-8,12-dien-2-yl]hexatriaconta-21,24-dienamide
C66H125NO4 (995.9608089999999)
N-[(4E,8E,12E)-1,3-dihydroxypentacosa-4,8,12-trien-2-yl]dotetracontanamide
C67H129NO3 (995.9971923999999)
(21Z,24Z)-N-[(8E,12E)-1,3,4-trihydroxyoctacosa-8,12-dien-2-yl]octatriaconta-21,24-dienamide
C66H125NO4 (995.9608089999999)
N-[(4E,8E,12E)-1,3-dihydroxynonacosa-4,8,12-trien-2-yl]octatriacontanamide
C67H129NO3 (995.9971923999999)
N-[(4E,8E,12E)-1,3-dihydroxyheptacosa-4,8,12-trien-2-yl]tetracontanamide
C67H129NO3 (995.9971923999999)
(21Z,24Z)-N-[(8E,12E)-1,3,4-trihydroxyhexacosa-8,12-dien-2-yl]tetraconta-21,24-dienamide
C66H125NO4 (995.9608089999999)
(21Z,24Z)-N-[(8E,12E)-1,3,4-trihydroxytetracosa-8,12-dien-2-yl]dotetraconta-21,24-dienamide
C66H125NO4 (995.9608089999999)
(21Z,24Z)-N-[(E)-1,3-dihydroxyheptacos-4-en-2-yl]tetraconta-21,24-dienamide
C67H129NO3 (995.9971923999999)
(Z)-N-[(4E,8E)-1,3-dihydroxypentacosa-4,8-dien-2-yl]dotetracont-21-enamide
C67H129NO3 (995.9971923999999)
(Z)-N-[(4E,8E)-1,3-dihydroxynonacosa-4,8-dien-2-yl]octatriacont-21-enamide
C67H129NO3 (995.9971923999999)
(21Z,24Z)-N-[(E)-1,3-dihydroxynonacos-4-en-2-yl]octatriaconta-21,24-dienamide
C67H129NO3 (995.9971923999999)
(21Z,24Z)-N-[(E)-1,3-dihydroxypentacos-4-en-2-yl]dotetraconta-21,24-dienamide
C67H129NO3 (995.9971923999999)
(Z)-N-[(4E,8E)-1,3-dihydroxyheptacosa-4,8-dien-2-yl]tetracont-21-enamide
C67H129NO3 (995.9971923999999)
(27Z,30Z)-N-[(E)-1,3-dihydroxynonacos-4-en-2-yl]octatriaconta-27,30-dienamide
C67H129NO3 (995.9971923999999)
(24Z,27Z,30Z)-N-(1,3-dihydroxynonacosan-2-yl)octatriaconta-24,27,30-trienamide
C67H129NO3 (995.9971923999999)
Diadenosine hexaphosphate
D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents